MedTrace Logo

Impact of APP-assisted Patient Management on the Quality Control of Blood Purification Therapy

NCT07291154 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 392

Last updated 2025-12-18

No results posted yet for this study

Summary

Many maintenance hemodialysis (MHD) patients develop negative outlooks due to their illnesses and complications, making their quality of life and prognosis a clinical concern. Effective life management and treatment cooperation are crucial to improving dialysis quality and patient outcomes. This trial aims to evaluate whether management through the "Yueya" mini-program and WeChat can provide personalized guidance such as health education, diet, exercise, medication supervision, and condition monitoring to enhance treatment compliance, quality of life, strengthen quality control in the hemodialysis unit, and improve patient prognosis.

Patients will be divided into a group receiving support via the "Yueya" mini-program and WeChat, and a control group receiving routine care. Clinical and laboratory indicators, cardiovascular events, death, hospitalization, quality of life, and compliance will be recorded and compared between groups to assess the impact of APP-assisted patient management on the quality of MHD blood purification therapy and the prognosis of MHD patients.

Conditions

  • End Stage Renal Disease (ESRD)
  • Maintenance Hemodialysis

Interventions

BEHAVIORAL

APP-based management

Based on patients' specific conditions such as age, gender, primary disease, and complications, the APP-based management will provide individualized and round-the-clock guidance for dialysis patients in their daily lives through the "Yueya" mini-program and WeChat. This guidance covers various aspects, including health knowledge education, diet and exercise guidance, medication supervision, condition monitoring, and real-time feedback.

Sponsors & Collaborators

  • Yunfeng Xia

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-22
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07291154 on ClinicalTrials.gov